Zobrazeno 1 - 10
of 7 802
pro vyhledávání: '"JAPANESE PATIENTS"'
Autor:
Makoto Kawashima, MD, PhD, Yoshiyuki Kaneko, BS, Manami Sawasaki, BS, Kyohei Masubuchi, BS, Hiroyuki Yasukawa, BS, Saki Okada, BS, Carolyn Enloe, MPH, Carri Geer, PhD, Martina Cartwright, PhD, Tomoko Maeda-Chubachi, MD, PhD, Takeshi Tani, BS
Publikováno v:
JAAD International, Vol 18, Iss , Pp 8-16 (2025)
Background: Molluscum contagiosum (MC) is a contagious viral skin infection. Berdazimer gel, 10.3% (SB206 12%) is approved in the United States as the first topical, at-home MC prescription medication. Objective: To assess safety and tolerability of
Externí odkaz:
https://doaj.org/article/33885ef1b86e4fde82f9446045c9c07a
Autor:
Kengo Matsumoto, Tsutomu Nishida, Dai Nakamatsu, Masashi Yamamoto, Koji Fukui, Osamu Morimura, Kinya Abe, Yukiyoshi Okauchi, Hiromi Iwahashi, Masami Inada
Publikováno v:
Clinics and Practice, Vol 14, Iss 4, Pp 1601-1614 (2024)
Background: The prognostic significance of liver dysfunction in COVID-19 patients remains unclear. In this study, we investigated the association between liver function test results and severe disease progression in COVID-19 patients. Methods: This r
Externí odkaz:
https://doaj.org/article/3fb348d659824a5d97c00d6170a917ec
Autor:
Akio Tanaka, Ken Igawa, Hidetoshi Takahashi, Ryosuke Shimizu, Yoko Kataoka, Hitoe Torisu-Itakura, Yoji Morisaki, Sonia Montmayeur, Norito Katoh
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Lebrikizumab has previously demonstrated efficacy in Phase 3 trials: ADvocate1 and ADvocate2 (as monotherapy), ADhere, and ADhere-J (in combination with topical corticosteroids). Here, the impact of lebrikizumab combined with low- to mid-potency topi
Externí odkaz:
https://doaj.org/article/d0701168569e406880f281dc5bf863a8
Autor:
S. Takei, A. Kawazoe, A. Jubashi, M. Komatsu, K. Sato, S. Mishima, D. Kotani, M. Yura, N. Sakamoto, S. Sakashita, T. Kuwata, T. Kojima, T. Fujita, T. Kinoshita, K. Shitara
Publikováno v:
ESMO Gastrointestinal Oncology, Vol 4, Iss , Pp 100050- (2024)
Background: Although the common treatment strategy for localized gastric cancer in Japan is gastrectomy followed by adjuvant chemotherapy, several randomized studies in non-Japanese populations have established perioperative chemotherapy as the stand
Externí odkaz:
https://doaj.org/article/fbe485f1762740a6b0142e7e0fcfe368
Publikováno v:
BioPsychoSocial Medicine, Vol 18, Iss 1, Pp 1-13 (2024)
Abstract Background In Europe, an herbal medicine containing peppermint oil is widely used in patients with irritable bowel syndrome (IBS). In Japan, however, no clinical evidence for peppermint oil in IBS has been established, and it has not been ap
Externí odkaz:
https://doaj.org/article/e24e46f6cac943169e1433e6fed1ca06
Autor:
Junichi Omura, Yogeshwar Makanji, Nobuhiro Tanabe, Dae Young Yu, Jin Yu Tan, Sooyeol Lim, Mahsa H. Kouhkamari, Jeremy Casorso, David Bin-Chia Wu, Paul Bloomfield
Publikováno v:
Pulmonary Therapy, Vol 9, Iss 4, Pp 511-526 (2023)
Abstract Introduction Real-world data on the comparative effectiveness of endothelin receptor antagonists (ERAs; macitentan, bosentan, ambrisentan) for pulmonary arterial hypertension (PAH), particularly in Asian countries, are scarce. We evaluated t
Externí odkaz:
https://doaj.org/article/84065d105090462abee8d697d08b7e49
Autor:
Hiroyuki Nishiyama, Yu Tanaka, Masahiro Hamada, Masahiko Ozaki, Toshihiko Minegishi, Yuichiro Ito, Shinichiroh Maekawa, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background This study was conducted to identify factors associated with the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma and to confirm the real-world safety and effectiveness of pembr
Externí odkaz:
https://doaj.org/article/e9e970c9534e430ba327aa4b8b5ff89f
Autor:
Yutaka Fujiwara, Yasutoshi Kuboki, Masayuki Furukawa, Nobumasa Mizuno, Hiroki Hara, Tatsuya Ioka, Makoto Ueno, Yasuo Takahashi, Shunji Takahashi, Shinji Takeuchi, Christine Lihou, Tao Ji, Chenwei Tian, Toshio Shimizu
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10597-10611 (2023)
Abstract Background FIGHT‐102 was a phase 1, dose‐escalation, dose‐expansion study of pemigatinib in Japanese patients with advanced solid tumors. Here, we report safety, tolerability, and preliminary efficacy of pemigatinib from FIGHT‐102. M
Externí odkaz:
https://doaj.org/article/9baedb4c4d12487081450e5da764609a
Autor:
Masatoshi Eto, Toshio Takagi, Go Kimura, Satoshi Fukasawa, Satoshi Tamada, Yuji Miura, Mototsugu Oya, Naoto Sassa, Satoshi Anai, Masahiro Nozawa, Hideki Sakai, Rodolfo Perini, Wataru Yusa, Hiroki Ikezawa, Tomoyuki Narita, Yoshihiko Tomita
Publikováno v:
Cancer Medicine, Vol 12, Iss 6, Pp 6902-6912 (2023)
Abstract Background The phase 3 CLEAR study demonstrated statistically significantly improved efficacy with lenvatinib plus pembrolizumab versus sunitinib, including progression‐free survival and overall survival, in patients with previously untrea
Externí odkaz:
https://doaj.org/article/8c1591921a074d1ba5b9e9d36660eacf
Autor:
Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano‐Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu
Publikováno v:
Cancer Medicine, Vol 11, Iss 24, Pp 4889-4899 (2022)
Abstract The autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell product, lisocabtagene maraleucel (liso‐cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This analysis assessed safety and efficacy of liso‐cel
Externí odkaz:
https://doaj.org/article/01555f722268410baca0cc3cbf1c71db